Key result
FGF21 attenuates pressure overload-induced cardiac hypertrophy by promoting PINK1-mediated mitophagy.
Why the study?
FGF21 expression increases in cardiac hypertrophy but fails to prevent heart failure, and the molecular mechanism of its beneficial effects on hypertrophic myocardial mitochondria remains unclear.
Does FGF21 signaling prevent cardiac hypertrophy by regulating PINK1-mediated mitophagy under pressure-overload conditions?
Does FGF21 signaling prevent cardiac hypertrophy by regulating PINK1-mediated mitophagy under pressure-overload conditions?
FGF21 protects against cardiac hypertrophy via the FGFR1-PINK1-mediated mitophagy pathway, providing a mechanistic explanation for why mismatched FGFR1 downregulation in heart failure may drive FGF21 resistance.
FGF21-PINK1 mitophagy axis merits targeted investigation in hypertrophy models; leaves open clinical translation pending human studies.
INTRODUCTION: Cardiac hypertrophy is an independent risk factor and the primary predictor of heart failure (HF). Mitochondria are crucial for the shift from hypertrophy to heart failure. The expression of fibroblast growth factor 21 (FGF21), a cardioprotective factor, is increased in patients with cardiac hypertrophy but fails to prevent heart failure. Additionally, the molecular mechanism through which FGF21 exerts its beneficial effects on hypertrophic myocardial mitochondria remains unclear. OBJECTIVES: Our study investigated the effect of FGF21 on cardiac hypertrophy, elucidating its mechanism of action through the enhancement of mitophagy-mediated cardioprotection. METHODS: A transverse aortic constriction (TAC) model and a phenylephrine (PE) model were applied to explore the effect and mechanism of FGF21. P62-mediated mitophagy inducer (PMI) and rapamycin (Rapa) were used to confirm that FGF21-regulated mitophagy under overload pressure conditions. RESULTS: FGF21 knockout markedly exacerbated TAC-induced cardiac function damage, mitochondrial damage, and mitophagy impairment. In vitro, FGF21 knockdown aggravated PE-induced cardiomyocyte hypertrophy and mitophagy dysfunction. FGF21 treatment promoted mitophagy in the TAC and PE models, but this effect was abolished in the absence of PTEN-induced putative kinase 1 (PINK1). The increase in PINK1 expression induced by Rapa can rescue impaired cardiac function and mitophagy impairment in FGF21-deficient TAC mice. Similarly, PMI enhances mitophagy, which inhibits damage to cardiac functions. A further study revealed that the expression of fibroblast growth factor receptor 1 (FGFR1) and FGF21 was opposite in heart failure. Knockdown of FGFR1 inhibited FGF21-mediated mitophagy. CONCLUSION: FGF21 promotes PINK1-mediated mitophagy to attenuate cardiac hypertrophy, and mismatched FGFR1 expression may hamper the beneficial effect of FGF21 on cardiac hypertrophy.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2025) studied Cardiac hypertrophy. FGF21 (Efruxifermin) or genetic modulation vs. Saline, solvent vehicle, sham surgery, or wild-type controls was evaluated on Cardiac hypertrophy (HW/BW ratio, cardiomyocyte cross-sectional area) and left ventricular ejection fraction (LVEF). FGF21 promoted PINK1-mediated mitophagy to attenuate pressure overload-induced cardiac hypertrophy, an effect that was abolished by PINK1 or FGFR1 deficiency.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: